Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma

Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma

Study of the activity of PD-1 inhibitors in metastatic uveal melanoma

The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.

Inclusion Criteria:

• Patients with metastatic uveal melanoma
• Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment

Exclusion Criteria:

• Antecedent of another evolutionary tumor pathology